Suchergebnisse - "Han, Xia"

PubPharm (4)

1

Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma : ELARA trial update

enthalten in: Blood | 2024

von Dreyling, M. | Fowler, N. | Dickinson, M. | +37

2

Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with r/r DLBCL : phase 1b PORTIA study results

enthalten in: Blood advances | 2023

von Jaeger, U. | Worel, N. | McGuirk, J. | +7

3

Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia

enthalten in: Blood cancer discovery | 2022

von Pulsipher, M. | Han, X. | Maude, S. | +19

CommentIn: Blood Cancer Discov. 2022 Jan;3(1):2-4. - PMID 35019857

4

Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET) : a multicentre, open-label, single-arm, phase 2 study

enthalten in: The Lancet. Oncology | 2021

von Schuster, S. | Tam, C. | Borchmann, P. | +26

CommentIn: Nat Rev Clin Oncol. 2021 Nov;18(11):676. - PMID 34580475

1
[1]